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Abstract Following their release from cells, ATP and
NAD, the universal currencies of energy metabolism,
function as extracellular signalling molecules. Mammalian
cells express numerous purinoceptors, i.e., the nucleotide-
gated P2X ion channels and the G-protein-coupled P2Y
receptors. Signalling through purinoceptors is controlled by
nucleotide-metabolizing ecto-enzymes, which regulate the
availability of extracellular nucleotides. These enzymes
include ecto-nucleoside triphosphate diphosphohydrolases
(ENTPD, CD39family)and ecto-nucleotidepyrophosphatase/
phosphodiesterases (ENPP, CD203 family). Investigation of
these receptors and enzymeshas been hampered by the lack of
available antibodies, especially ones that recognize these
proteins in their native conformation. This study reports the
use of genetic immunization to generate such antibodies
against P2X1,P 2 X 4,P 2 X 7, ENTPD1, ENPTD2, ENPTD5,
ENPTD6, ENPP2, ENPP3, ENPP4, ENPP5, and ENPP6.
Genetic immunization ensures expression of the native
protein by the cells of the immunized animal and yields
antibodies directed against proteins in native conformation
(ADAPINCs). Such antibodies are especially useful for
immunofluorescence and immunoprecipitation analyses,
whereas antibodies against synthetic peptides usually function
well only in Western-blot analyses. Here we illustrate the utility
of the new antibodies to monitor the cell surface expression
of and to purify some key players of purinergic signalling.
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Abbreviations
ADAPINCs Antibodies directed against proteins in native
conformation
AEBSF 4-(2-Aminoethyl) benzenesulfonyl fluoride
hydrochloride
ATP Adenosine triphosphate
ENPP Ecto-nucleotide pyrophosphatase/
phosphodiesterase
ENTPD Ecto-nucleoside triphosphate diphosphohy-
drolase
NAD Nicotinamide adenine dinucleotide
PO Peroxidase
PVDF Polyvinylidene difluoride
Introduction
Following their release from cells, the universal currencies
of energy metabolism, ATP and NAD, function as extra-
cellular signalling molecules [1–5]. Molecular cloning has
identified 7 nucleotide-gated ion channels (P2X purinocep-
tors) and >8 nucleotide-activated G-protein-coupled recep-
tors (P2Y purinoceptors) [6–10]. Signaling through
Purinergic Signalling (2007) 3:359–366
DOI 10.1007/s11302-007-9084-9
Friedrich Haag and Friedrich Koch-Nolte share senior authorship.
Sina Möller and Caroline Jung contributed equally to this study.
S. Möller:C. Jung: S. Adriouch: G. Dubberke: F. Seyfried:
F. Haag (*):F. Koch-Nolte
Institute of Immunology, Hamburg University Medical Center,
Campus Forschung 2.OG; Rm. 02.059, Martinistr. 52,
20246 Hamburg, Germany
e-mail: haag@uke.uni-hamburg.de
S. Adriouch: M. Seman: F. Haag:F. Koch-Nolte
INSERM U519,
Rouen, Francepurinoceptors is effectively controlled by nucleotide-
metabolizing ecto-enzymes, which regulate the availability
of extracellular nucleotides [11]. Prominent roles are played
by members of two families of ecto-enzymes: the ecto-
nucleoside triphosphate diphosphohydrolases (ENTPD,
CD39 family) [12] and the ecto-nucleotide pyrophosphatase/
phosphodiesterases (ENPP, CD203 family) [13].
The mammalianP2Xfamilyencompasses sevenmembers.
All P2X purinoceptors contain cytosolic N- and C-terminal
tails, two membrane spanning domains, and an extracellular
domain of approximately 280 amino acids containing the
ligand-binding site and 10 conserved cysteine residues that
likely form five intrachain disulfide bonds [14, 15]. The
extracellular domains of the respective mouse and human
P2X orthologues show high (ca. 80–90%) sequence identity;
the paralogues within a given species show lower (40–50%)
identity.
The mammalian ENTPD family encompasses eight
members [16]. ENTPD1–4, 7 and 8 have a structure similar
to that of P2X purinoceptors, i.e., cytosolic N- and C-
terminal tails, two transmembrane spanning domains, and an
extracellular domain of approximately 440 amino acids,
encompassing the ligand-binding site and four conserved
cysteines likely engaged in intrachain disulfide bridges [12].
ENTPD1–3 and 8 are expressed as cell surface enzymes,
ENTPD4 and ENTPD7 as luminal enzymes of intracellular
organelles. ENTPDases share structural similarities with the
actin/HSP70/sugar kinase superfamily [12]. ENTPD5 and
ENTPD6 lack the second transmembrane region. Moreover,
in ENTPD5, the region corresponding to the first transmem-
brane domain of the other family members is N-terminal and
functions as a signal peptide, resulting in the secretion of
ENTPD5 into the lumen of the endoplasmic reticulum.
ENTPD6 is a type II transmembrane protein. ENTPD
orthologues show high (ca. 80–90%) sequence identity; the
paralogues within a given species show lower (30–50%)
identity.
The ENPP family encompasses seven members [13].
ENPP1–3 are type II transmembrane proteins with a
structure analogous to that of ENTPD6, i.e., an N-terminal
cytosolic tail, a single transmembrane domain and an
extracellular catalytic domain of approximately 400 amino
acids. ENPP4–7, in contrast, are type I membrane proteins.
A hydrophobic N-terminus acts as a signal peptide, the
extracellular catalytic domain is followed by a single
transmembrane domain and a short C-terminal cytosolic
tail. ENPPs 4–7 consist of catalytic domains only, the
catalytic domains of ENPPs 1–3 are flanked by genetically
fused upstream somatomedin B and downstream nuclease-
like domains [13]. ENPPs share structural similarities with
the alkaline-phosphatase superfamily [17, 18]. The catalytic
domain of ENPP orthologues shows high (ca. 80–90%)
sequence identity; the paralogues within a given species
show lower (40–50%) identity.
Despite their relevance for purinergic signalling, inves-
tigation of these receptors and enzymes has been hampered
by the lack of available antibodies, especially ones that
recognize the enzymes in their native conformation. Anti-
bodies raised by immunization with synthetic peptides
derived from the known amino acid sequence of a protein
of interest generally work well in Western-blot analyses but
often fail to recognize the native protein on the cell surface
(Fig. 1). Such antibodies can be used successfully for
monitoring the overall expression level of the protein of
interest in a population of cells but cannot be used to assess
cell surface expression on individual cells. Genetic immu-
nization, in contrast, ensures that the protein of interest is
expressed in native conformation by the cells of the
Fig. 1 DNA immunization vs.
peptide immunization
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proteins in native conformation (ADAPINCs) [19, 20].
Such antibodies function well in immunofluorescence,
FACS, ELISA, and immunoprecipitation analyses, i.e.,
assays in which antipeptide antibodies often fail. We have
previously employed this technique to generate highly
specific polyclonal and monoclonal antibodies against ecto-
ADP-ribsoyltransferases and against murine P2X7 [20–23].
Here we report the generation and characterization of similar
antibodies against other key players of purinergic signalling
and illustrate the utility of these antibodies for monitoring
the cell surface expression of their cognate antigens.
Materials and methods
Cloning of expression vectors and cell transfections
Clones encoding full-length open-reading frames represent-
ing members of the P2X, ENTPD, and ENPP families were
purchased from the mammalian genome collection (www.
rzpd.de). Clones that were not already in an expression
vector (pCMV-SPORT6) were subcloned into the pCDNA6
expression vector. Further expression constructs were
kindly provided by James Wiley, Sydney (human P2X7),
Richard J. Evans, Leicester (human P2X1), François
Rassendren, Montpellier (mouse P2X4), Ruth Murrell-
Lagnado, Cambridge (rat P2X4), and Astrid Kehlen, Halle
(hENPP2). An expression construct for nuclear green
fluorescent protein was generated by cloning the DNA-
binding domain of the LKLF transcription factor [24]a sa
C-terminal fusion protein into the pEGFP-N1 vector
(Clontech). Expression constructs were transfected into
CHO and HEK cells (5 μg for purinoceptors and ecto-
enzymes and/or 0.5 μg eGFP-LKLF per T25 flask con-
taining 2×10
6 cells) with the JetPei transfection reagent
(Q-Biogen). For stable transfections, plasmids were line-
arized with Ssp1o rSca1 before transfection, and stable
transfectants were selected by cultivating cells in the pres-
ence of 12 μg/ml blasticidin (Sigma).
Genetic immunization and purification of antibodies
Genetic immunizations were performed as described [20,
22]. In brief, rabbits or rats were immunized four times by
ballistic DNA immunization with plasmid-conjugated gold
particles. Serum samples were obtained 10 days post-
immunization. For monoclonal antibody production, ani-
mals received a final boost with transiently transfected
HEK cells (2×10
6 cells in 200 μl PBS i.v.) 3 days prior to
sacrifice. Splenocytes were fused to Sp2/0 myeloma cells
and screened for production of specific antibodies by
immunofluorescence analysis of CHO cells that had been
co-transfected 20–42 h earlier with constructs encoding
eGFP-LKLF and the protein of interest. Antibodies were
purified by affinity chromatography on Protein G Sepharose
(Pharmacia), and conjugated to Alexa488 according to the
manufacturer’s (Molecular Probes) instructions. Antibodies
directed against the C-terminal peptides of P2X purinocep-
tors were purchased from Caltag (rat P2X1, Cal), ABCAM
(rat P2X4, Abc), and Alomone (mouse P2X7, Al). The L4
anti-human P2X7 mAb was kindly provided by Dr. Ian
Chessel at Glaxo Wellcome (Middlesex, UK).
Immunofluorescence analyses
CHO cells were co-transfected with expression constructs
for purinoceptors or ecto-enzymes and nuclear GFP (5 and
0.5 μg/10
6 cells, respectively). Cells were transferred onto
96-well plates (4×10
5 cells/well) 6 h post-transfection.
Then, 20 h after transfection, cells were fixed for 10 min in
2% paraformaldehyde (PFA) and then stained with serial
dilutions of immune serum for 30 min at room temperature.
To detect ENTPD5, which is not bound to the cell surface,
cells were fixed in 4% PFA and subsequently permeabilized
with 0.5% IGEPAL (Sigma) before staining. Bound
antibody was detected with PE-conjugated antirat or
antirabbit IgG (1:100) (Dianova). Cell nuclei were counter-
stained with Hoechst 33342. Cells were analyzed with a
Zeiss Axiovert 25 microscope equipped with the Canon
PowerShot G2 digital camera and appropriate filters for
visualizing Hoechst stain (Zeiss filter set 01), green
fluorescent protein (Zeiss filter set 10) and PE fluoro-
chrome (Zeiss filter set 15). Photographs were taken at 40×
magnification with fixed camera settings (digital zoom:
4.3×, aperture: 5.0, exposure time: 2 s for GFP and PE,
1/8 s for Hoechst 33342). GFP and PE images were merged
using Adobe Photoshop software.
FACS analyses
For FACS analyses, cells were harvested by brief trypsini-
zation (5 min at room temperature) and washed in serum-
containing medium. Cells (5×10
5/100 μl) were stained
either directly with Alexa-488-conjugated antibodies (1 μg)
or with serially diluted immune serum followed by PE-
conjugated antirat or antirabbit IgG (1:100, Dianova).
Gating was performed on living cells on the basis of
propidium iodide exclusion.
Immunoprecipitation analyses
Antibodies were conjugated to Protein G Sepharose beads
(Pharmacia) (1 μg antibody/20 μL beads in 200 μL PBS con-
taining 1% Triton X-100) by incubation on a roller for 30 min
at room temperature. Beads were washed twice in PBS/1%
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(10
7/ml) were lysed in PBS, 1% Triton-X100, 1 mM AEBSF
(Sigma) for 20 min at 4°C. Insoluble material was pelleted by
centrifugation, and the cleared lysates (2×10
6 cells in 200 μL)
were subjected to immunoprecipitation using 20 μL antibody-
conjugated beads by incubation on a roller for 30 min at room
temperature. Beads were washed four times in PBS/1% Triton
X-100. Proteins were eluted from the beads by incubation in
SDS-PAGE sample buffer for 15 min at 70°C. Eluted proteins
were size-fractionated on precast SDS-PAGE gels (Invitrogen)
and blotted onto PVDF membranes. Purinoceptors and ecto-
enzymes were detected with serially diluted serum followed
by peroxidase (PO)-conjugated antirabbit IgG (1:5,000) using
the ECL system (Amersham).
Immunoblot analyses
Cells (10
7/ml) were pelleted by centrifugation and lysed by
resuspension in SDS-PAGE sample buffer (Invitrogen).
DNA was sheared by brief ultrasonication on ice (two 15-s
pulses with an MSE ultrasonicator at maximum power
setting). Insoluble material was pelleted by centrifugation,
and soluble proteins (5×10
5 cell equivalents/lane) were
size-fractionated on precast SDS-PAGE gels (Invitrogen)
under reducing conditions and blotted onto PVDF mem-
branes. Purinoceptors and ecto-enzymes were detected with
serially diluted serum followed by PO-conjugated antirabbit
IgG (1:5,000) using the ECL system (Amersham).
Results and discussion
Use of transiently transfected CHO cells to assess
the specificity and titres of antisera against purinoceptors
and ecto-enzymes
Antibodies raised by genetic immunization of rabbits and
rats with cDNA expression constructs for purinoceptors,
ENTPDs, and ENPPs were assayed for reactivity and
specificity by indirect immunofluorescence staining of
CHO cells, 24 h after cotransfection with a construct
encoding nuclear GFP and the cDNA expression construct
used for immunization (Fig. 2 and Table 1). By this time,
transfected cells were clearly distinguishable from untrans-
fected cells by virtue of their green fluorescent nuclei
(Fig. 2). Specific antibodies were detected on the basis of
bright cell surface staining of transfected cells and lack of
reactivity with untransfected cells. Antipeptide antisera
against the same antigens, in contrast, did not show any
detectable reactivity in this assay (Table 1).
Monitoring cell surface expression of purinoceptors
and ecto-enzymes by flow cytometry
The utility of the ADAPINC antisera for monitoring cell
surface expression was assessed further by flow cytometry
(FACS analyses) of transiently transfected HEK cells
(Fig. 3). The results confirm that the antisera react
Fig. 2 Immunofluorescence analyses of CHO cells following tran-
sient cotransfection with expression constructs for nuclear green
fluorescent protein (GFP) and purinoceptors (a), CD39-like ENTPDs
(b), and CD203-like ENPPs (c). CHO cells were cotransfected with
nuclear GFP and expression constructs for the indicated purinoceptors
or ecto-enzymes. Twenty hours after transfection, cells were stained
with serial dilutions of the indicated antisera followed by PE-
conjugated antirabbit IgG. To detect non-membrane-bound ENTPD5,
intracellular staining was performed by fixing and permeabilizing
cells. Cell nuclei were counterstained with Hoechst 33342. Cells were
analyzed with a Zeiss Axiovert 25 microscope equipped with filters
for visualizing Hoechst dye, GFP, and PE fluorochrome. Panels show
merged images for Hoechst dye and GFP (b, c, left panels) or for GFP
and PE (a–c, right panels)
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they do not react with untransfected HEK cells. Impor-
tantly, the antisera recognize the respective purinoceptor/
ecto-enzyme on the cell surface of living cells. In contrast,
antipeptide antisera against the same antigens did not show
any detectable reactivity with the transfected cells in these
assays. Further, the use of the ADAPINC antisera for FACS
analyses permits an assessment of the relative expression
level of the cognate protein on the cell surface of individual
cells as well as an assessment of the number of transfected
vs. untransfected cells in the cell population. These
b
Table 1 Titres, specificities, and applications of antibodies against
members of the families of P2X purinoceptors, CD39-like ENTPDs,
and CD203-like ENPPs
Antibody Host Titre Specificity FACS/
IFT
Western
blot
P2X family
9316 rb 1:800 hP2X1 +++ (+)
RG2 rt 1:800 hP2X1 +++ ++
CR29 rb 1:1600 hP2X4 +++ ++
CR30 rb 1:1600 mP2X1 +++ ++
116 rb 1:800 mP2X4
RG22 rt 1:1600 mP2X4 +++ +++
K1G rb 1:1600 mP2X7 +++ −
RH23 rt 1:1600 mP2X7 ++ −
Hano43 rt mAb mP2X7 ++ −
3428 rb 1:1600 rP2X7 ++ −
Calt rb 1:2000 rP2X1 − +++
Abc rb 1:2000 rP2X4 − +++
Al rb 1:5000 mP2X7 − +++
ENTPD family
5441 rb 1:1600 hENTPD2 +++ −
RG10 rt 1:1000 h/mENTPD2 +++ nd
RG10-B28 rt mAb hENTPD2 +++ nd
5446 rb 1: 400 hENTPD5 +++ −
CR44 rb 1:6400 mENTPD1 +++ +++
RG9 rt 1:1600 mENTPD1 +++ nd
RG9-A59 rt mAb mENTPD1 +++ −
CR45 rb 1:1600 mENTPD2 +++ +
CR63 rb 1:1600 mETNTPD2 +++ nd
CR46 rb 1:400 mENTPD5 +++ −
CR47 rb 1:200 mENTPD6 +++ −
ENPP family
K2G rb 1:200 hENPP2 +++ nd
7619 rb 1:800 hENPP2 +++ nd
CR65 rb 1:800 mENPP4 +++ nd
CR66 rb 1:400 mENPP5 +++ nd
CR67 rb 1:800 mENPP6 +++ nd
7620 rb 1:3200 rENPP3 +++ nd
Fig. 3 FACS analyses of purinoceptor (a) and ecto-enzyme (b)
expression by transfected HEK cells. HEK cells were transfected with
expression constructs for the indicated purinoceptors and ecto-enzymes.
Then, 24 h post-transfection, cells were harvested by brief trypsinization
and single cell suspensions were stained with serial dilutions of the
indicated antisera followed by PE-conjugated antirabbit IgG before FACS
analyses. Control stainings were performed with untransfected cells
(shaded histograms in a, dotted lines in b) and with cells transfected
with the species orthologue (red lines in a)
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blot analyses, since for these analyses, lysates are prepared
from cell populations. We further used the FACS-based
assay system to test whether the antisera crossreact with
other members (paralogues) of the receptor/enzyme family
and/or the same receptor/enzyme (orthologue) in other
species (human, rat, or mouse). The results reveal that most
antisera are specific for the receptor/enzyme used for
immunization and do not cross-react with other members
of the same protein family. Some antisera, however, did
react with the orthologous protein, in particular at low
dilutions, e.g., antiserum CR30 raised against mouse P2X1
shows some reactivity with the human P2X1 orthologue
(Fig. 3a).
Some of the antisera recognize the denatured cognate
antigen in Western-blot analyses
We next tested the utility of the ADAPINC antisera for
monitoring overall protein expression levels in immunoblot
analyses (Fig. 4). To this end, we size-fractionated the
proteins from lysates of untransfected and of transiently
transfected HEK cells by SDS-PAGE followed by immuno-
blot analyses. The results show that only some of the
ADAPINC antisera detected bands of the expected size. For
comparison, we again performed parallel analyses with
antisera raised against the same proteins by peptide immuni-
zation. The results show that the antipeptide sera generally
detected bands of the expected size. The C-terminal peptide is
commonly used for peptide immunization. In the case of
P2X7, this sequence is highly conserved between rat, mouse
and human orthologues, and the corresponding antipeptide
serum recognized the respective orthologues (not shown). In
contrast, in the case of P2X4, the mouse and human
Fig. 4 Immunoblot analyses of purinoceptor (a) and ecto-enzyme (b)
expression by transfected HEK cells. Untransfected (u) or HEK cells
transfected with mouse (m) or human (h) purinoceptors or ecto-
enzymes were solubilized 24 h post-transfection with SDS-PAGE
sample buffer. Proteins in cell lysates were size-fractionated by SDS-
PAGE and subjected to immunoblot analyses using the indicated
antisera. Bound antibodies were detected with peroxidase-conjugated
secondary antibody and the ECL system
Fig. 5 Immunoprecipitation of purinoceptors by antibodies raised via
genetic immunization. Untransfected (u) and transfected (t) HEK cells
were solubilized 24 h post-transfection with PBS/1% Triton X-100.
Purinoceptors were immunoprecipitated from cell lysates by incuba-
tion with the indicated antisera bound to Protein G Sepharose.
Precipitates were subjected to immunoblot analysis as in Fig. 4, using
the indicated antipeptide antisera for detection
364 Purinergic Signalling (2007) 3:359–366sequences differ in two and five positions, respectively, from
the rat peptide used for immunization, and this antipeptide
serum shows only weak cross-reactivity with these ortho-
logues (Fig. 4a, Abc α-mP2X4).
Affinity purification of purinoceptors and ecto-enzymes
Finally, we tested the utility of the ADAPINC antisera for
immunoprecipitation of the cognateproteins from cell lysates
(Fig. 5). To this end, we prepared lysates of untransfected
and of transiently transfected HEK using the nondenaturing
nonionic detergent Triton-X-100. Lysates were incubated
with ADAPINC antibodies immobilized on protein-G
sepharaose beads, and proteins bound to washed beads
were subsequently analyzed by SDS-PAGE followed by
immunoblot analyses with antipeptide antibodies. The
results show that all of the ADAPINC antisera efficiently
precipitated proteins of the expected size from cell lysates.
This underscores the utility of these antibodies for purifying
native receptors and ecto-enzymes from lysed cells.
Conclusion
Using genetic immunization, we have raised highly specific
polyclonal and monoclonal antibodies against key players
of purinergic signalling, i.e., P2X1,P 2 X 4,a n dP 2 X 7
purinoceptors and ENTPD1, ENPTD2, ENPTD5,
ENPTD6, ENPP2, ENPP3, ENPP4, ENPP5, and ENPP6
enzymes. Our findings underscore the utility of genetic
immunization for generating highly specific polyclonal and
monoclonal antibodies directed against proteins in native
conformation (ADAPINCs) [19, 20]. These antibodies are
valuable tools for assessing the expression levels of the
native protein by immunofluorescence analyses and flow
cytometry, i.e., assays in which antipeptide antibodies often
fail. The antibodies described here provide useful tools for
further characterization of the structure and function of
these purinoceptors and ecto-enzymes.
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